Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
Muriel Le Romancer(Université Claude Bernard Lyon 1), Laura Corbo(Centre National de la Recherche Scientifique), Stéphanie Sentis(Lyon 1 Université), Jack‐Michel Renoir(Université Paris-Sud), Coralie Poulard(Université Claude Bernard Lyon 1), Pascale A. Cohen(Lyon 1 Université)
Cited by 302
Related Papers
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
|Pharmacological Reviews|2006|430
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
|Endocrine Related Cancer|2006|239
Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
|Recent Patents on Anti-Cancer Drug Discovery|2009|162
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
|International Journal of Cancer|2009|131